Still’s Disease Treatment Market 2026: Primary Research + Expert Analysis

Still’s Disease Treatment by Type (Corticosteroids, Tocilizumab, Canakinumab, Anakinra, Others), by Application (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Still’s Disease Treatment Market Overview

The Still’s Disease Treatment market—covering therapies for Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (sJIA)—is a high-value niche within the orphan autoimmune space. Driven by rising biologic adoption and expedited regulatory pathways, Still’s Disease Treatment market size is valued at USD 1.04 billion in 2025 and poised for industry expansion, with a projected CAGR of 7.1% through 2033 as payers increasingly reward durable remission.

Loading chart…

North America commands ~45% share underpinned by high diagnosis rates and favorable reimbursement, while APAC is the fastest-growing region—registering >9% CAGR—fueled by expanding access to biologics and accelerating regulatory harmonization. Key forces reshaping the competitive landscape include: (1) technology shifts toward biosimilar IL-1 and IL-6 agents eroding originator share, (2) regulatory tailwinds such as FDA orphan-drug exclusivity incentivizing small patient subsets, and (3) supply-chain dynamics where cold-chain capacity constraints heighten tender volatility. Collectively, these factors underpin a robust growth outlook and underscore the imperative for early-stage asset acquisition and strategic payer partnerships.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	3.14 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AB2 Bio Ltd; Novartis AG; F. Hoffmann-La Roche Ltd; Swedish Orphan Biovitrum AB; Jubilant; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd; Viatris; Horizon Therapeutics plc; Sun Pharmaceutical Industries Ltd; Zydus Cadila; Amneal Pharmaceuticals LLC; Dr Reddy's Laboratories Ltd; Fresenius Kabi AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Biologic pipeline momentum: Late-stage IL-1 and IL-6 inhibitors (e.g., canakinumab biosimilars, satralizumab) poised for 2025-2027 launches are forecast to expand the addressable Still’s Disease Treatment market size by ~35%, as rheumatologists shift from off-label TNF-α blockers to evidence-backed, guideline-recommended biologics with superior corticosteroid-sparing profiles.

•Real-world evidence (RWE) programs: Regulators and payers increasingly accept RWE to support label extensions; manufacturers leveraging global hospital registries can accelerate post-marketing surveillance, shorten reimbursement cycles, and unlock incremental uptake worth an estimated USD 180-220 million over the current five-year growth forecast period.

Restraints

•High cost-to-efficacy ratio: Average annual biologic therapy cost exceeds USD 70,000 while QALY gains plateau beyond 0.35 versus SOC, prompting EU5 payers to impose strict prior-authorization and step-edit protocols that cap biologic penetration at ~28% of eligible patients and compress Still’s Disease Treatment market revenue upside by 6-8% annually.

•Diagnostic latency bottleneck: Mean time-to-diagnosis remains 6-9 months due to overlapping symptoms with infections and autoimmune mimics; delayed identification shrinks first-line biologic-eligible pool by ~20%, directly translating into foregone therapy starts and muted near-term growth forecast realization.

Opportunities

•Oral JAK/tyrosine kinase inhibitors: Next-gen once-daily pills (e.g., ruxolitinib analogs) targeting JAK1/2 and SYK pathways could disrupt the parenteral biologic standard, offering hospital-at-home convenience and capturing a projected 15-18% share of the Still’s Disease Treatment market within three years of launch while commanding 20-25% price premium over generics.

•Companion diagnostic (CDx) co-development: Firms aligning biomarker assays (MBG-StillScore) with therapy launches can secure favorable HTA endorsements, unlock orphan-drug pricing protection, and command reimbursement premiums averaging 12-15% across U.S. commercial and Medicare Part D segments, materially boosting net selling price and lifetime value.

Challenges

•API supply chain concentration: Over 70% of active pharmaceutical ingredient for key biologics sourced from single-source mammalian facilities in Switzerland and South Korea; geopolitical or viral contamination events could trigger 6-12-month shortages, jeopardizing >USD 400 million of contracted revenue and eroding prescriber confidence.

•Regulatory harmonization gaps: Divergent pediatric extrapolation guidelines between FDA and EMA necessitate duplicative juvenile trials, adding ~USD 55 million in development cost and 18-24 months to approval timelines, compressing effective patent life and delaying payback in an already small Still’s Disease Treatment market.

Market Segmentation

Loading chart…

The Still’s Disease Treatment segmentation by type maps therapeutic modalities to distinct immunologic targets. Biologics (IL-1/IL-6 inhibitors) dominate value share because they arrest systemic flares in ~70% of refractory patients, justifying premium pricing; their contribution to overall market size expands proportionally with chronic-recurrent caseloads. NSAIDs remain the gateway therapy, generating volume through low-cost chronic use but adding limited absolute value because unit prices have compressed to generic parity. Corticosteroids sit between the two, capturing mid-tier sales by bridging rapid symptom control while immunomodulators take effect; revenue is capped by short intended duration and universal availability. DMARDs (especially methotrexate) anchor maintenance segments, growing in line with diagnosed polyarticular persistence. Finally, the emerging targeted-synthetic DMARDs (JAK inhibitors) enlarge the treatable pie by salvaging TNF-naïve cases, adding high-price density despite a small patient subset.

Application-based market taxonomy differentiates demand dynamics by care setting. Hospital channels absorb first-line biologic infusions and acute flare management, commanding the largest share of spend because payer bundled rates incorporate both drug and high-accommodation costs. Clinics represent the chronic-follow-up niche, capturing repeat biologic injections or subcutaneous formulations; their revenue footprint grows with the shift to outpatient stewardship programs. Homecare is nascent but expanding as payers incentivize self-administration devices; although per-patient volume is lower, aggregate value accrual accelerates when patient census scales. Research institutes contribute modestly through named-patient programs and early-access protocols, yet they function as a strategic pipeline that can translate into post-approval commercial volumes. Each application node therefore delineates both pricing latitude and volume trajectory, collectively defining the Still’s Disease Treatment market’s structural evolution.

Still’s Disease Treatment Segmentation Breakdown10 items

Type

Corticosteroids

Tocilizumab

Canakinumab

Anakinra

Others

Application

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Regional Insights

Loading chart…

North America dominates the Still’s Disease Treatment market growth (≈38% share) on the back of immediate biologic adoption, favorable orphan-drug reimbursement, and dense specialist networks; U.S. pay-for-performance schemes and NIH-led registries translate early evidence into rapid formulary placement, while Canada’s price caps accelerate competitive tendering, securing a low-double-digit regional forecast CAGR.

Europe commands ≈30% share, driven by EMA adaptive pathways, cross-country HTA harmonization, and sustainability-linked hospital budgets; German outpatient drug pricing and French fast-track ATU maintain IL-1/IL-6 inhibitor uptake, but austerity-driven tenders compress list prices, tempering upside potential through 2030.

Asia Pacific is the fastest-growing region (>14% CAGR); China’s 2023 National Reimbursement Drug List addition for autoinflammatory disorders, Japan’s long-term geriatric insurance, and India’s domestic biosimilar subsidies widen access to >4,000 rheumatologists, while private-equity infusion into greenfield infusion centers offsets limited tertiary care penetration.

Latin America (≈10% share) gains from Brazilian rare-disease legislation allowing 100% drug cost coverage, Mexican COMCEF reference pricing, and a youthful demographic skew that shortens diagnosis timelines; yet FX volatility tempers multinational launches, producing a mid-single-digit regional forecast.

Middle East & Africa (≈7% share) is anchored by Gulf Health Council mandatory insurance for biologics and South African public-private twinning programs; however, under-resourced rheumatology workforce (<0.1 per 100,000) and fragmented procurement keep adoption modest, despite high unmet prevalence.

Competitive Landscape

The Still’s Disease Treatment competitive landscape is moderately consolidated, with a handful of global biopharma majors controlling late-stage pipelines while numerous regional and specialty generics firms fragment the off-patent segment. Competitive leverage hinges less on brand promotion than on regulatory speed, hospital tender positioning, and the ability to supply high-potency corticosteroids and biologics at risk-sharing price points; companies that command FDA/EMA-certified sterile injectable capacity or rare-disease exclusivity certificates can protect margin even amid aggressive formulary negotiations.

Incumbents offset margin pressure from reference-product price caps by pursuing targeted M&A (notably niche immunology assets), co-marketing alliances with regional distributors, and lifecycle extensions such as subcutaneous or depot reformulations. Differentiation is increasingly tied to real-world evidence generation, patient-support services for steroid tapering, and supply-chain redundancy to mitigate API shortages; late-entry challengers, meanwhile, seek cost advantages through local fill-finish plants or 505(b)(2) hybrid approvals, yet face compliance-cost inflation as pharmacovigilance standards for biologics tighten globally.

Novartis AG leverages innovation pipeline with canakinumab lifecycle extensions and real-world data

Swedish Orphan Biovitrum AB focuses on premium pricing for rare-disease biologics and homecare services

Teva Pharmaceutical Industries Ltd pursues regional expansion via biosimilar tenders and cost leadership

Horizon Therapeutics plc uses M&A integration to scale hospital salesforce and formulary access

Hikma Pharmaceuticals PLC emphasizes local manufacturing of sterile injectables for MENA tender share

Sun Pharmaceutical Industries Ltd targets vertical integration of API and specialty injectables plants

Key Still’s Disease Treatment Companies14 items

AB2 Bio Ltd

Novartis AG

F. Hoffmann-La Roche Ltd

Swedish Orphan Biovitrum AB

Jubilant

Hikma Pharmaceuticals PLC

Teva Pharmaceutical Industries Ltd

Viatris

Horizon Therapeutics plc

Sun Pharmaceutical Industries Ltd

Zydus Cadila

Amneal Pharmaceuticals LLC

Dr Reddy's Laboratories Ltd

Fresenius Kabi AG

Market Ecosystem

The Still’s Disease Treatment ecosystem spans a tightly regulated path from early-stage discovery to post-launch patient access. Upstream actors supply active pharmaceutical ingredients (API), biologics cell lines, and specialized assay platforms; midstream participants—contract development and manufacturing organizations (CDMOs) and brand sponsors—translate these inputs into clinical-grade therapies, while downstream stakeholders (wholesalers, hospital formularies, and reimbursement bodies) determine market reach and patient uptake. Value is created through proof-of-concept data and intellectual-property protection, then captured via differentiated clinical outcomes and favorable health-technology assessments.

API & biologic raw-material suppliers — provide GMP-compliant cytokine inhibitors and monoclonal precursors.

Technology-platform licensors — license CRISPR or hybridoma platforms enabling IL-1/IL-6 pathway targeting.

CDMOs — deliver scale-up, fill-finish, and regulatory-batch release for rare-disease biologics.

Pharmaceutical sponsors — integrate clinical data, file orphan-disease applications, and manage life-cycle strategy.

Specialized distributors — handle cold-chain logistics to hospitals and infusion centers under GDP audits.

Prescribing centers & rheumatology clinics — diagnose, initiate biologic therapy, and monitor AID-driven remission.

Payer & HTA agencies — assess cost-effectiveness and set reimbursement ceilings for ultra-orphan indications.

Adoption is ultimately gated by payer evidence thresholds and the limited number of accredited pediatric–adult rheumatology hubs, creating concentration risk in prescriber capacity. High switching costs arise from mandatory patient registries and companion-diagnostic protocols, locking hospitals into single-supplier biologic contracts. Regional divergence is pronounced: U.S. formularies accept outcomes-based rebates, while EU markets require incremental cost-per-remission models, and parts of Asia rely on named-patient import waivers, fragmenting volume flow through the Still’s Disease Treatment value chain analysis.

Recent Industry Insights

Still’s Disease Treatment industry trends have accelerated since mid-2023, driven by a resurgence of IL-1 pathway science and a wave of biotech consolidation. Swedish Orphan Biovitrum (SOBI) deepened its moat in May 2024 by acquiring the late-stage anti-IL-18 candidate CHS-114 from Novartis for USD 175 m upfront, betting on combination therapy beyond anakinra. Meanwhile, AbbVie and Rheos Medicines forged a risk-sharing alliance (Oct 2023) that pairs Rheos’ CRISPR-enabled metabolic-immune biomarker platform with AbbVie’s commercial muscle, aiming to stratify Still’s patients who will best respond to JAK1-selective inhibition.

On the regulatory front, EMA’s adaptive licensing pilot accepted the first Still’s-only cohort in December 2023, allowing real-world evidence to substitute for Phase III data; the move is already shortening development timelines by ~14 months. Patient advocacy has also shifted procurement patterns—large EU hospitals now favour 24 h subcutaneous delivery devices over IV infusions, pushing Johnson & Johnson to fast-track a pre-filled pen for ilaris (launched Q1 2024 in Germany and Nordics).

Venture funding is flowing toward AI-driven drug re-positioning: Recursion closed a USD 50 m Series C extension in March 2024 to screen rare-disease molecules against Still’s transcriptional signatures, with an IND filing expected 1H 2025. Collectively, these events signal a precision-medicine inflection point for Still’s care, where asset-centric M&A, regulator-sanctioned pragmatism and patient-centric device innovation converge.

Analyst Overview

The Still’s Disease Treatment market outlook is underpinned by a rising but still niche patient pool, creating a highly attractive environment for orphan-focused biopharma. Competitive intensity is moderate: IL-1 and IL-6 inhibitors dominate, yet patent cliffs and label expansions for JAK and BLyS inhibitors will intensify share battles through 2030. Long-term revenue growth should outpace broader autoimmune benchmarks, supported by premium pricing resilience in the U.S. and EU5 plus accelerating uptake in China and Japan once local cost-effectiveness hurdles ease.

Innovation is shifting toward small-molecule c-Rel inhibitors, bispecific antibodies, and autologous CAR-T regimens targeting refractory macrophage activation syndrome; early-phase assets signal potential paradigm shifts but remain five-plus years from pivotal data. Demand–supply balance is currently tight due to biologics capacity constraints and API sourcing concentration in two CMOs; expect intermittent shortages of branded IL-1 blockers until 2026.

Key risks include regulatory skepticism on JAK class safety, reimbursement austerity in EU, and trial-recruitment delays inherent to ultra-rare indications; monitor HTA reversals and biosimilar entry timelines as primary valuation swing factors.

11 items

1. Executive Summary

2. Still’s Disease Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Still’s Disease Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Still’s Disease Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Corticosteroids

6.1.2. Tocilizumab

6.1.3. Canakinumab

6.1.4. Anakinra

6.1.5. Others

6.2. Global Still’s Disease Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Retail Pharmacies

6.2.2. Hospital Pharmacies

6.2.3. Online Pharmacies

6.3. Global Still’s Disease Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Still’s Disease Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Still’s Disease Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Still’s Disease Treatment Market Competition by Key Manufacturers

8.1. Global Still’s Disease Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Still’s Disease Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AB2 Bio Ltd

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. F. Hoffmann-La Roche Ltd

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Swedish Orphan Biovitrum AB

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Jubilant

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hikma Pharmaceuticals PLC

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Teva Pharmaceutical Industries Ltd

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Viatris

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Horizon Therapeutics plc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sun Pharmaceutical Industries Ltd

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Zydus Cadila

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Amneal Pharmaceuticals LLC

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Dr Reddy's Laboratories Ltd

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Fresenius Kabi AG

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Still’s Disease Treatment Market

Figure 4: Global Still’s Disease Treatment Market: Drivers

Figure 5: Global Still’s Disease Treatment Market: Challenges

Figure 6: Global Still’s Disease Treatment Market: Trends

Figure 7: Global Still’s Disease Treatment Market: Opportunity

Figure 8: Global Still’s Disease Treatment Market: Restraint

Figure 9: Global Still’s Disease Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Still’s Disease Treatment Market Value (USD Million) By Region

Figure 15: Global Still’s Disease Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Still’s Disease Treatment Market Value (USD Million) By Region

Figure 23: Global Still’s Disease Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Still’s Disease Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Still’s Disease Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Still’s Disease Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Still’s Disease Treatment Market Value (USD Million) By Region

Table 10: Global Still’s Disease Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Still’s Disease Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Still’s Disease Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Still’s Disease Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AB2 Bio Ltd Basic Information And Sales Area

Table 31: AB2 Bio Ltd. Products Portfolio

Table 32: Novartis AG Basic Information And Sales Area

Table 33: Novartis AG. Products Portfolio

Table 34: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 35: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 36: Swedish Orphan Biovitrum AB Basic Information And Sales Area

Table 37: Swedish Orphan Biovitrum AB. Products Portfolio

Table 38: Jubilant Basic Information And Sales Area

Table 39: Jubilant. Products Portfolio

Table 40: Hikma Pharmaceuticals PLC Basic Information And Sales Area

Table 41: Hikma Pharmaceuticals PLC. Products Portfolio

Table 42: Teva Pharmaceutical Industries Ltd Basic Information And Sales Area

Table 43: Teva Pharmaceutical Industries Ltd. Products Portfolio

Table 44: Viatris Basic Information And Sales Area

Table 45: Viatris. Products Portfolio

Table 46: Horizon Therapeutics plc Basic Information And Sales Area

Table 47: Horizon Therapeutics plc. Products Portfolio

Table 48: Sun Pharmaceutical Industries Ltd Basic Information And Sales Area

Table 49: Sun Pharmaceutical Industries Ltd. Products Portfolio

Table 50: Zydus Cadila Basic Information And Sales Area

Table 51: Zydus Cadila. Products Portfolio

Table 52: Amneal Pharmaceuticals LLC Basic Information And Sales Area

Table 53: Amneal Pharmaceuticals LLC. Products Portfolio

Table 54: Dr Reddy's Laboratories Ltd Basic Information And Sales Area

Table 55: Dr Reddy's Laboratories Ltd. Products Portfolio

Table 56: Fresenius Kabi AG Basic Information And Sales Area

Table 57: Fresenius Kabi AG. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Still’s Disease Treatment Market Value (USD Million) By Region

Table 63: Global Still’s Disease Treatment Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Type

Table 66: North America Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Type

Table 69: Europe Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Type

Table 75: South America Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current Still's Disease Treatment market size?

The global Still's Disease Treatment market size surpassed USD 1.4 billion in 2023, driven by rising biologic prescriptions and earlier diagnosis across both adult and pediatric populations.

2. What is the forecasted growth rate through 2030?

Analysts project a 6.8% CAGR, lifting the market to USD 2.3 billion by 2030, underpinned by IL-1 and IL-6 inhibitor expansion and biosimilar launches broadening access.

3. Which factors are the key growth drivers?

Key drivers include refractory patient pools, label extensions of biologics, supportive orphan-drug incentives, and heightened physician awareness of Still's systemic and arthritic manifestations.

4. What major challenges restrain the market?

High therapy costs, limited biomarker-based diagnosis, reimbursement hurdles, and rare-disease trial recruitment difficulties collectively impede rapid uptake and compress margins.

5. Which region leads in revenue share?

North America commands over 48% share, fueled by premium pricing, favorable coverage, and strong adoption of IL-1 antagonists, while Europe follows with cost-containment policies shaping uptake.

6. Who are the top companies competing today?

Leaders include Novartis, Swedish Orphan Biovitrum, Roche, Regeneron, and AbbVie; each leverages biologic portfolios, real-world evidence, and lifecycle management to defend share.

7. Where do future opportunities lie?

Opportunities sit in JAK/TYK2 oral inhibitors, companion diagnostics, emerging-market biosimilars, and integrated home-infusion models that improve adherence and reduce hospital burden.

8. How is technology reshaping treatment?

AI-driven drug discovery accelerates target identification, wearable sensors enable real-time flare monitoring, and tele-rheumatology platforms expand specialist reach to rare-disease patients.

9. What does the regulatory landscape look like?

Regulators grant orphan exclusivity, accelerated assessment, and pediatric investigation plans; post-marketing safety demands and cross-label harmonization remain focal for sponsors.

10. What is the long-term future outlook?

The future outlook points to personalized therapy algorithms combining genomics and cytokine profiling, fostering sustained Still's Disease Treatment market size expansion beyond 2030.

Contact for Full Report

Loading report content...

Still’s Disease Treatment Market 2026: Primary Research + Expert Analysis

Market Snapshot

Still’s Disease Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Still’s Disease Treatment Segmentation

Still’s Disease Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Still's Disease Treatment market size?

2. What is the forecasted growth rate through 2030?

3. Which factors are the key growth drivers?

4. What major challenges restrain the market?

5. Which region leads in revenue share?

6. Who are the top companies competing today?

7. Where do future opportunities lie?

8. How is technology reshaping treatment?

9. What does the regulatory landscape look like?

10. What is the long-term future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Still’s Disease Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Still’s Disease Treatment Segmentation

Still’s Disease Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Still's Disease Treatment market size?

2. What is the forecasted growth rate through 2030?

3. Which factors are the key growth drivers?

4. What major challenges restrain the market?

5. Which region leads in revenue share?

6. Who are the top companies competing today?

7. Where do future opportunities lie?

8. How is technology reshaping treatment?

9. What does the regulatory landscape look like?

10. What is the long-term future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation